Sustained release oral fampridine in the treatment of multiple sclerosis

Bibliography

• Blight A. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bulletin 1989;22(1):47-52
   PubMed Web of Science ®Google Scholar
• Bostock H, Sears T, Sherratt R. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 1981;313:301-15
   PubMed Web of Science ®Google Scholar
• Bowe C, Kocsis J, Targ E, Waxman S. Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Annals of Neurology 1987;22(2):264-8
   PubMedGoogle Scholar
• Bowman W, Savage A. Pharmacological actions of aminopyridines and related compounds. Rev Pure Appl Pharmacol Sci 1981;2(4):317-71
   PubMedGoogle Scholar
• Glover W. The aminopyridines. General Pharmacology 1982;13(4):259-85
   PubMedGoogle Scholar
• Gold M, Shuster M, Levine J. Characterization of six voltage-gated K+ currents in adult rat sensory neurons. J Neurophysiology 1996;75(6):2629-46
   PubMed Web of Science ®Google Scholar
• Sherratt R, Bostock H, Sears T. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283(5747):570-2
   PubMed Web of Science ®Google Scholar
• Shi R, Blight A. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77(2):553-62
   PubMed Web of Science ®Google Scholar
• Shi R, Kelly T, Blight A. Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. Exp Neurology 1997;148(2):495-501
   PubMed Web of Science ®Google Scholar
• Targ E, Kocsis J. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Research 1985;328(2):358-61
   PubMed Web of Science ®Google Scholar
• Weinshenker B, Wingerchuk D. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 2008;318:343-56
   PubMed Web of Science ®Google Scholar
• Lucchinetti C. Pathological heterogeneity of idiopathic central nervous system inflammatory demyelinating disorders. Curr Top Microbiol Immunol 2008;318:19-43
   PubMedGoogle Scholar
• Franklin R, Kotter M. The biology of CNS remyelination: the key to therapeutic advances. J Neurol 2008;255(Suppl 1):19-25
   PubMed Web of Science ®Google Scholar
• Lassmann H, Brück W, Lucchinetti C. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17(2):210-8
   PubMed Web of Science ®Google Scholar
• Blight A, Toombs J, Bauer M, Widmer W. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dugs: a phase I clinical trial. J Neurotrauma 1991;8(2):103-19
   PubMed Web of Science ®Google Scholar
• Stefoski D, Davis F, Faut M, et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurology 1987;21(71-77)
   PubMedGoogle Scholar
• Stefoski D, Davis F, Fitzsimmons W, et al. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41(1344-1348)
   PubMedGoogle Scholar
• Schwid D, Petrie M, McDermott M, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21
   PubMed Web of Science ®Google Scholar
• Goodman A, Brown T, Cohen J, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
   PubMed Web of Science ®Google Scholar
• Bever C, Young D, Anderson P, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994;44(1054-1059)
   Google Scholar
• Polman C, Bertelsmann F, van Loenen A, et al. 4-Aminopyridine in the treatment of patients with multiple sclerosis, long term efficacy and safety. Arch Neurol 1994;51:292-6
   PubMed Web of Science ®Google Scholar
• Goodman A, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebocontrolled, dose-ranging study. Mult Scler 2007;13:357-68
   PubMed Web of Science ®Google Scholar
• Goodman A, Brown T, Krupp L, et al. Randomized, double-blind, placebo-controlled trial of sustained release oral fampridine in multiple sclerosis. Lancet 2009;323(9665):732-8
   Google Scholar
• Cohen J, Cutter G, Fischer J, et al. Use of the Multiple Sclerosis Functional Composite as an outcome measure in a Phase 3 clinical tria Arch Neurol 2001;58:961-7
   PubMed Web of Science ®Google Scholar
• Kaufman M, Moyer D, Norton J. The significant change for the timed 25-foot walk in the multiple sclerosis functional composite. Mul Scler 2000;6:286-90
   PubMed Web of Science ®Google Scholar
• Hobart J, Riaz A, Lamping DL, et al. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60:31-6
   PubMed Web of Science ®Google Scholar
• Goodman A. World Congress Presentation MS-F204 17 Sept 2008 FINAL. In: World Congress on Treatment and Research in Multiple Sclerosis. Montreal, CA, 2008
   Google Scholar
• Burton J, Bell C, Walker S, O'Connor P. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008;71(22):1833-4
   PubMed Web of Science ®Google Scholar
• Poser C, Brinar V. Epilepsy and multiple sclerosis. Epilepsy Behav 2003;4(6):6-12
   PubMed Web of Science ®Google Scholar
• Cohen J, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000;54:802-6
   PubMed Web of Science ®Google Scholar
• Kragt J, van der Linden FAH, Nielson JM, et al. Clinical impact of 20% worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis. Mult Scler 2006;12:594-498
   PubMed Web of Science ®Google Scholar
• Schwid S, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology1997;49:1419-24
   PubMed Web of Science ®Google Scholar
• Schwid S, Goodman AD, McDermott MP, et al. Quantitative functional measures in MS: what is a reliable change? Neurology 2002;58:1294-96
   PubMed Web of Science ®Google Scholar
• Kryscio R. Fampridine for MS responders: clinical relevant or hypothesis generating? [editorial]. Neurology 2008;71:1130-1
   PubMed Web of Science ®Google Scholar